MPN Clinical Trials

Clinical trials are an important step in the process of discovering new treatments for MPNs. The decision to participate in a clinical trial is one you should carefully consider. It is important to discuss clinical trial participation with your family and your physician. We've compiled a FAQ to assist patients who are considering participating in a clinical trial.

The MPN Research Foundation has complied a list of trials, some of which are currently recruiting patients:

If you are a company or investigator who is running a trial and you need to make a change to the listing for your trial contact our office at 312-683-7243 or by sending an email.

Find a Clinical Trial

Click the boxes below to filter clinical trials by disease type.

All
Myelofibrosis (MF)
Essential Thrombocythemia (ET)
Polycythemia Vera (PV)
MF

Pacritinib

Persist-2: A randomized, controlled Phase 3 study of oral Pacritinib vs. best available therapy in patients with thrombocytopenia and primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis

For trial locations and more information, click here.

MF

PF-04449913

PF-04449913 Single-Agent In Patients With Myelofibrosis Previously Treated With a Janus Kinase Inhibitor

Pfizer Clinical Trial Call Center: 1-800-718-1021 or contact us here

MF

Alisertib (MLN8237)

A Multicenter, Open-Label, Pilot Study of Alisertib (MLN8237), A Novel Inhibitor of Aurora Kinases, in Adult Patients with Relapsed/Refractory Acute Megakaryoblastic Leukemia or Myelofibrosis (Including Primary and Post-Essential/Post-Polycythemic Myelofibrosis)

For more information about this study please contact us at: 312.472.123 or at nmdti@northwestern.edu

MF

Momelotinib

Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF

For more information, email momelotinib.studies@gilead.com

Full details available here.

MF

Mirabegron

Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation

Contact: Andrea Fuhrer, PhD at +41 31 389 92 63 or andrea.fuhrer@sakk.ch

MF

Ruxolitinib with Allogeneic Hematopoeitic Cell Transplantation

Exploring the Potential of Dual Kinase JAK 1/2 Inhibitor Ruxolitinib (INC424) with Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis.

Contact: Sara Duffey, Clinical Research and Education Specialist , Robert H. Lurie Comprehensive Cancer Center at 312.695.1102 or cancertrials@northwestern.edu

MF

P1101

Phase II Study of P1101 in Early Myelofibrosis

Sponsor: Pharmassentia

Note: The study is now open to Early stage MF (low or intermediate 1 stage) as well as intermediate-2 or high risk MF patients either not eligible for ruxolitinib or having failed under ruxolitinib.

Contact: Allison Rosenthal at Rosenthal.Allison@mayo.edu

MF

Nivolumab

Study of Nivolumab in Patients With Myelofibrosis

Contact: Srdan Verstovsek, MD at 713-792-7305

MF

Imetelstat (Telomerase inhibitor)

Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor

Contact: Laurie Sherman at lsherma4@its.jnj.com

MF

PRM-151

A Phase 2, Prospective Study of PRM-151 In Subjects With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), Or Post-Essential Thrombocythemia MF (post-ET MF)

Contact: info@promedior.com

MF

Ruxolitinib & BKM120

A Study to Find the Maximum Tolerated Dose of the Experimental Combination of Drugs INC424 and BKM120 in Patients With Primary or Secondary Myelofibrosis

Contact: Novartis at 41-61-3241111

MF

Ruxolitinib & Decitabine

Multicenter phase I/II trial of ruxolitinib in combination with decitabine in patients with accelerated phase MPN or post-MPN AML

Contact: Jill Kleczko at jill.kleczko@mssm.edu,

Raajit Rampal at 212-639-2194, or

John Mascerenhas at john.mascarenhas@mssm.edu

MF

Ruxolitinib & SCT

Exploring the potential of dual kinase JAK1/2 inhibitor Ruxolitinib (INC424) with reduced intensity allogenic hematopoeitic stem cell transplantation in patients with myelofibrosis (MPD-RC #114)

Contact: Jill Kleczko at jill.kleczko@mssm.edu,

Vikas Gupta at 416-946-4521,

Adam Mead at adam.mead@imm.ox.ac.uk OR 44-0-1865-222325, or

John Mascarenhas at john.mascarenhas@mssm.edu

MF

Ruxolitinib & LDE225

A Phase1b/11 Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Contact: Novartis at 41-61-3241111

MF

Ruxolitinib & Panobinostst

Panobinostat and Ruxolitinib in myelofibrosis (Prime Study) - Phase I/II study of combination oral JAK2 tyrosine kinase inhibotor (JAK2-TKI) and histone deacetylase inhibitor (HDACI) therapy in patients with myelofibrosis

Contact: Jill Kleczko at jill.kleczko@mssm.edu or

John Mascarenhas at john.mascarenhas@mssm.edu

MF

Ruxolitinib & Danazol

A phase 2 pilot trial of Ruxolitinib combined with Danazol for patients with primary myelofibrosis, post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis suffering from anemia

Contact: Jill Kleczko at jill.kleczko@mssm.edu or

John Mascarenhas at john.mascarenhas@mssm.edu or

Ruben Mesa at mesa.ruben@mayo.edu

MF

Pomalidomide

Study of Pomalidomide in Persons with Myelofibrosis (RESUME)

Contact: Mary Bartlett at 913-266-0513 or mbartlett@celgene.com

Alyce Kay at 913-266-0369 or akay@celgene.com

MF

* LCL-161

Phase 2 LCL-161 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF) or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

Contact: Naveen Pemmaraju, MD at 713-792-4956

MF

Oral Arsenic

Study of Oral Arsenic Trioxide With or Without Ascorbic Acid in Adults with Myelofibrosis

Contact: Roswell Park Cancer Center Institute at 877-275-7724 or askrpci@rosewellpark.org

MF

Panobinostat

LBH589 (Pabinostat) for the Treatment of Myelofibrosis

Contact: Jill Kleczko at jill.kleczko@mssm.edu OR 212-241-0573

MF

* NS-018

Safety and Tolerability Study of Oral NS-018 in Patients with Primary Myelofibrosis (MF), Post-PV MF or Post-ET MF

For more information, contact Tomonori Uno of NS Pharma at: uno@nspharma.com

MF

Momelotinib (formerly CYT387)

Momelotinib Versus Ruxolitinib in Patients with Myelofibrosis

For more information, email momelotinib.studies@gilead.com or click here.

MF

INC424

INC424 for Patients with Myelofibrosis (JUMP)

Contact: Novartis Pharmaceuticals at +1-862-778-8300

MF

Ruxolitinib & Pracinostat

Evaluation of Ruxolitinib & Pracinostat Combination as a therapy for Patients with Myelofibrosis

Contact: Srdan Verstovsek, MD, PhD at 713-745-3429

MF

LY2784544, Accrued all patients. Data expected in late 2015 or early 2016

Study of LY2784544 Testing Alternative Dosing in Patients with MF

Contact: 877-CTLILLY (877-285-4559) Mon-Fri, from 9AM to 5PM EST

MF

Pegasys

A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms (DALIAH)

Contact: Thomas S. Larsen at thomas.stauffer.larsen@ouh.regionsyddanmark.dk or

Sally Grant at sally.grant@ouh.regionsyddanmark.dk

MF

TAK-901

A Phase 1 Dose Escalation Study of TAK-901 in Subjects with Advanced Hematological Malignancies

Contact: Millennium Medical or Drug Info Center at 877-674-3784 OR medical@mlnm.com

MF

Sotatercept (ACE-011)

Phase II, open-label study of sotatercept (ACE-011) in subjects with MF & significant anemia

Contact: Srdan Verstovsek, MD, PhD, at 713-745-3429

MF

Correlative Bio-Marker Study

Correlative Biomarker Study in Patients with Myeloproliferative Disorders

Contact: Rona S. Weinberg, PhD at 212-570-3412 OR rweinberg@nybloodcenter.org

Ronald Hoffman, MD at 212-241-2297 OR ronald.hoffman@mssm.edu

MF

AZD1480 Accrued all patients

Study to Assess the Safety of AZD1480 in Patients with Myeloproliferative Diseases (MF, post PV/ET MF)

Contact: Srdan Vertosvesk at sverstov@mdanderson.org OR 713-745-3429

MF

Lestaurtinib Accrued all patients

CEP-701 (Lestaurtinib) in Myelofibrosis

Contact: Jill Kleczko at 212-241-0573

MF

Research Tissue Bank

Study allows for the preservation and storage of a small portion of tissues to be used for the study of MPDs.

Contact: Rona S. Weinberg, PhD at 212-570-3412 OR rweinberg@nybloodcenter.org

MF

SL-401

Phase I/II trial of SL-401 in patients with advanced, high risk MPNs, including MF, CMML, advanced systemic mastocytosis and HES/CEL

Contact: Srdan Verstovsek, MD, PhD at 713-745-3429

MF

Pegasys Accrued all patients

Pegasys in Patients with Myeloproliferative Diseases

Contact: Srdan Verstovsek at 713-745-3429 OR sverstov@mdanderson.org

ETMFPV

Mirabegron

Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation

Contact: Andrea Fuhrer, PhD at +41 31 389 92 63 OR andrea.fuhrer@sakk.ch

ET

* Anegrelide

Anegrelide Retard in Essential Thrombocythemia (TEAM-ET)

Visit clinicaltrials.gov

ETMFPV

* Ruxolitinib and Decitabine

Multicenter phase I/II trial of ruxolitinib in combination with decitabine in patients with accelerated phase MPN or post-MPN AML

Contact: Jill Kleczko at jill.kleczko@mssm.edu

John Mascarenhas at john.mascarenhas@mssm.edu

Ruben Mesa at mesa.ruben@mayo.edu

ET

* Anagrelide and Hydroxyurea

A Study of Anagrelide and Hydroxyurea in High-Risk ET

Contact: 866-842-5335

PV

Pegylated Interferon

AOP2014 in patients with Polycythemia Vera who previously participated in the PROUD-PV study

Contact: Michael Zoerer at michael.zoerer@aoporphan.com / 43+1+5037244-46 OR check clinicaltrials.gov

ETPV

Momelotinib Accrueda all patients

Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia

Contact: momelotinib.studies@gilead.com

PV

* AOP2014 and Hydroxyurea

Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera (PROUD-PV)

Contact: Michael Zoerer at 43+1+5037244-46 , OR michael.zoerer@aoporphan.com

ETPV

* Pegasys and Hydroxyurea

Randomized Trial of Pegylated Interferon Alfa-2a vs. Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

Contact: William M. Garrett Associate Director, Clinical Operations Incyte Corporation at 302-498-6987

PV

Ruxolitinib and Hydroxyurea, accrued all patients

Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study

Contact: William M. Garrett Associate Director, Clinical Operations Incyte Corporation at 302-498-6987

ET

* Anagrelide Retard

Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential Thrombocythaemia (ARETA)

Contact: Michael Zoerer at 43+1+5037244-46, OR michael.zoerer@aoporphan.com

ETMFPV

Gale401

A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders

This study is no longer recruiting subjects. Results are expected to be published during Q4 2015 approximately.

ETMFPV

LY2784544

A study of LY2784544 in participants with myeloproliferative neoplasms

Contact: 877-CTLILLY (877-285-4559) Mon-Fri from 9 AM to 5 PM EST

ETMFPV

* Familial Study of MPDs

Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes

Contact: Dr. Josef Prchal at 801-581-4220 or Kim Hickman at 801-581-3707

ETMFPV

*Fludarabine

Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies

Illinois contacts: Damiano Rondelli at drond@uic.edu

Mariela Girotti at mgirotti@uic.edu

PV

INC424

Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: The RESPONSE Trial

Contact: William Garrett at 302-498-6987 OR wgarrett@incyte.com

Amy Blithe at 302-498-7079 OR ablithe@incyte.com

ETPV

Pegasys

Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

Contact: Dr. Ronald Hoffman at ronald.hoffman@mssm.edu or 212-241-2296

ETMFPV

*Pegasys

A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms (DALIAH)

Contact: Thomas S. Larsen at thomas.stauffer.larsen@ouh.regionsyddanmark.dk

Sally Grant at sally.grant@ouh.regionsyddanmark.dk

PV

PEG-P-INF -alpha 2b (P1101)

Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera (PEGINVERA)

Contact: Michael Zoerer at michael.zoerer@aoporphan.com / 43+1+5037244-46

ETMFPV

* n/a

Familial Myeloproliferative Disorders

Contact: Josef Prchal at 801-585-3229 / josef.prchal@hsc.utah.edu

Neeraj Ajarwal at 801-585-3229

ETPV

* Pegasys

Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)

Contact: Jill Kleczko at jill.kleczko@mssm.edu

ET

SPD422

Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults with At Risk Essential Thrombocythemia

Contact: 866-842-5335

ET

Xagrid

Safety and Pregnancy Outcomes in Thrombocythemia Patients Exposed to Xagrid Compared to Other Treatments

Contact: 866-842-5335

SPD422

Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults with At Risk Essential Thrombocythemia

Contact: 866-842-5335

Xagrid

Safety and Pregnancy Outcomes in Thrombocythemia Patients Exposed to Xagrid Compared to Other Treatments

Contact: 866-842-5335

ETPV

Open Label Study of Single Agent Oral RG7388

Sponsor: John Mascerenhas

Contact: John Mascarenhas, MD at (212) 241-3417 or john.mascarenhas@mssm.edu

Jill Kleczko at (212)241-0573 or jill.kleczko@mssm.edu

ETMFPV

ON HOLD Study: Persist-2

A randomized, controlled Phase 3 study of oral Pacritinib vs. best available therapy in patients with thrombocytopenia and primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis

Sponsor: CTI Biopharma and Baxalta

Contact: www.persistprogram.com

ETMFPV

Phase 2 LCL-161

For Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF) or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

Sponsor: MD Anderson in collaboration with Novartis

Contact: Serge Verstovsek, MD at 713-792-7305 or sverstov@mdanderson.org

x

NEVER MISS AN UPDATE

Get free, timely information on living with an MPN.

Subscribe